高级检索
当前位置: 首页 > 详情页

Crosstalk between ACE2 and PLGF regulates vascular permeability during acute lung injury

| 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Dept Emergency, Shijiazhuang 050011, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Surg, Shijiazhuang 050011, Peoples R China
出处:
ISSN:

关键词: Acute lung injury (ALI) Angiotensin converting enzyme 2 (ACE2) placental growth factor (PLGF) vessel permeability

摘要:
Angiotensin converting enzyme 2 (ACE2) treatment suppresses the severity of acute lung injury (ALI), through antagonizing hydrolyzing angiotensin II (AngII) and the ALI-induced apoptosis of pulmonary endothelial cells. Nevertheless, the effects of ACE2 on vessel permeability and its relationship with placental growth factor (PLGF) remain ill-defined. In the current study, we examined the relationship between ACE2 and PLGF in ALI model in mice. We used a previously published bleomycin method to induce ALI in mice, and treated the mice with ACE2. We analyzed the levels of PLGF in these mice. The mouse lung vessel permeability was determined by a fluorescence pharmacokinetic assay following i.v. injection of 62.5 mu g/kg Visudyne. PLGF pump or soluble Flt-1 (sFlt-1) pump was given to augment or suppress PLGF effects, respectively. The long-term effects on lung function were determined by measurement of lung resistance using methacholine. We found that ACE2 treatment did not alter PLGF levels in lung, but antagonized the effects of PLGF on increases of lung vessel permeability. Ectogenic PLGF abolished the antagonizing effects of ACE2 on the vessel permeability against PLGF. On the other hand, suppression of PLGF signaling mimicked the effects of ACE2 on the vessel permeability against PLGF. The suppression of vessel permeability resulted in improvement of lung function after ALI. Thus, ACE2 may antagonize the PLGF-mediated increases in lung vessel permeability during ALI, resulting in improvement of lung function after ALI.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q3 ONCOLOGY
最新[2024]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Emergency, Shijiazhuang 050011, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Hosp 4, Dept Surg, Shijiazhuang 050011, Peoples R China [*1]Department of Surgery, Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42314 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号